View Future GrowthNexgenRx 과거 순이익 실적과거 기준 점검 4/6NexgenRx의 수입은 연평균 -40.8%의 비율로 감소해 온 반면, Insurance 산업은 수입이 연평균 14.6% 증가했습니다. 매출은 연평균 11%의 비율로 증가해 왔습니다. NexgenRx의 자기자본이익률은 16.9%이고 순이익률은 5.9%입니다.핵심 정보-40.81%순이익 성장률-41.05%주당순이익(EPS) 성장률Insurance 산업 성장률8.02%매출 성장률11.01%자기자본이익률16.92%순이익률5.90%최근 순이익 업데이트31 Dec 2025최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Apr 21NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026.공시 • Apr 02NexgenRx Inc., Annual General Meeting, May 21, 2026NexgenRx Inc., Annual General Meeting, May 21, 2026.공시 • Dec 12NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025.공시 • Aug 19NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025.공시 • Apr 18Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025.공시 • Mar 28NexgenRx Inc., Annual General Meeting, May 15, 2025NexgenRx Inc., Annual General Meeting, May 15, 2025.공시 • Nov 26Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024NexgenRx Inc. announced a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of the Company's outstanding common shares. The dividend will be payable on or before December 20, 2024 to all shareholders of record as at the close of business on December 16, 2024.공시 • Oct 01NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of DirectorsNexgenRx Inc. announced the appointment of Linda Brennan to its Board of Directors effective immediately. Linda Brennan currently serves as Chief Financial Officer, Corporate Secretary and a Director of PJX Resources Inc. Ms. Brennan has been a consultant for 12 years, providing strategic advice and organizing and structuring financings to numerous early stage companies in the junior resource sector. She brings knowledge of finance, accounting and public markets to NexgenRx. She has served in the capacity of corporate secretary for several TSX-V listed companies. Ms. Brennan holds Business Administration and Bachelor of Commerce degrees from the University of Victoria and Royal Roads University, respectively.공시 • Jun 15NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024NEXGENRX INC. announced that a dividend in the amount of $0.005 has been declared in respect of all of its outstanding common shares. This dividend will be payable on or before June 30, 2024 to all shareholders of record as at the close of business on June 24, 2024.공시 • May 18Charles Burns Tenders Resignation as Director of NexgenRx IncNexgenRx Inc. announced that at the annual and special meeting of shareholders held on May 16, 2024, one of the Directors, Charles Burns was duly elected although the number of votes 'Withheld' exceeded the number of votes cast 'For' his election and based on the Company's Majority Voting Policy, Mr. Burns has tendered his resignation as a director of the Company. The Board has determined to delay acceptance of Mr. Burns' resignation until such time as a qualified candidate can be appointed to fill the vacancy created by this resignation, which is expected to occur on or before September 30, 2024.공시 • Apr 03NexgenRx Inc., Annual General Meeting, May 16, 2024NexgenRx Inc., Annual General Meeting, May 16, 2024.공시 • Dec 30NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of DirectorsNEXGENRX INC. announced the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive role in the industry and as such will be devoting 100% of his time to this new endeavour.공시 • Dec 21NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024NEXGENRX INC announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before January 4, 2024 to all shareholders of record as at the close of business on December 29, 2023.공시 • Jun 16NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before June 30, 2023 to all shareholders of record as at the close of business on June 23, 2023. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding.공시 • May 19NexgenRx Inc. Appoints Dave Bennett as New DirectorNexgenRx Inc. at its AGM held on May 19, 2023, approved the election of Mr. Dave Bennett as new director. Mr. Bennett is a seasoned senior executive and actuary with more than 30 years' experience working in the life insurance and wealth management industries. Most recently, he was at The Equitable Life of Canada, where he led the Group Benefits business for six years. Prior to that, he was the Chief Financial Officer of the company, responsible for all financial oversight, strategic planning and corporate business development. He also has extensive experience in strategy, with time spent at McKinsey & Co, and led the Mergers and Acquisitions function at Manulife. Mr. Bennett attained his ICD.D in 2022 and has served on a number of not-for-profit boards such as Grand River Hospital, the Waterloo District School Board, and as the Chair of an independent school. He also has considerable experience working with boards as management, having been accountable to the Audit and Pension committees of Equitable Life's Board of Directors for 7 years, and leading strategic reviews.매출 및 비용 세부 내역NexgenRx가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:NEGX.F 매출, 비용 및 순이익 (CAD Millions)날짜매출순이익일반관리비연구개발비31 Dec 2518111030 Sep 2518111030 Jun 2517111031 Mar 2517011031 Dec 2416011030 Sep 2416011030 Jun 2415011031 Mar 2415010031 Dec 2314-110030 Sep 231409030 Jun 231309031 Mar 231309031 Dec 221308030 Sep 221338030 Jun 221347031 Mar 221247031 Dec 211246030 Sep 211126030 Jun 211126031 Mar 211126031 Dec 201127030 Sep 201017030 Jun 201007031 Mar 201008031 Dec 191007030 Sep 19907030 Jun 19907031 Mar 19807031 Dec 187-16030 Sep 186-16030 Jun 186-15031 Mar 186-15031 Dec 176-15030 Sep 17604030 Jun 17604031 Mar 17614031 Dec 16614030 Sep 16504030 Jun 16504031 Mar 16504031 Dec 15504030 Sep 15504030 Jun 154040양질의 수익: NEGX.F는 고품질 수익을 보유하고 있습니다.이익 마진 증가: NEGX.F의 현재 순 이익률 (5.9%)은 지난해 (2.5%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: NEGX.F의 수익은 지난 5년 동안 연평균 40.8% 감소했습니다.성장 가속화: 지난 1년간 NEGX.F 의 수익 증가율(154.2%)은 연간 평균(-40.8%)을 초과합니다.수익 대 산업: NEGX.F의 지난 1년 수익 증가율(154.2%)은 Insurance 업계의 36.2%를 상회했습니다.자기자본이익률높은 ROE: NEGX.F의 자본 수익률(16.9%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YInsurance 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/21 13:34종가2026/03/23 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스NexgenRx Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 21NexgenRx Inc. announces Semi-Annual dividend, payable on April 28, 2026NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on April 28, 2026, ex-date on April 24, 2026 and record date on April 24, 2026.
공시 • Apr 02NexgenRx Inc., Annual General Meeting, May 21, 2026NexgenRx Inc., Annual General Meeting, May 21, 2026.
공시 • Dec 12NexgenRx Inc. announces Semi-Annual dividend, payable on December 19, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on December 19, 2025, ex-date on December 17, 2025 and record date on December 17, 2025.
공시 • Aug 19NexgenRx Inc. announces Semi-Annual dividend, payable on August 29, 2025NexgenRx Inc. announced Semi-Annual dividend of CAD 0.0050 per share payable on August 29, 2025, ex-date on August 25, 2025 and record date on August 25, 2025.
공시 • Apr 18Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or before April 30, 2025NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares. The dividend will be payable on or before April 30, 2025 to all shareholders of record as at the close of business on April 25, 2025.
공시 • Mar 28NexgenRx Inc., Annual General Meeting, May 15, 2025NexgenRx Inc., Annual General Meeting, May 15, 2025.
공시 • Nov 26Nexgenrx Inc. Declares Dividend on Common Shares, Payable on or Before December 20, 2024NexgenRx Inc. announced a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of the Company's outstanding common shares. The dividend will be payable on or before December 20, 2024 to all shareholders of record as at the close of business on December 16, 2024.
공시 • Oct 01NexgenRx Inc. Announces Appointment of Linda Brennan to Its Board of DirectorsNexgenRx Inc. announced the appointment of Linda Brennan to its Board of Directors effective immediately. Linda Brennan currently serves as Chief Financial Officer, Corporate Secretary and a Director of PJX Resources Inc. Ms. Brennan has been a consultant for 12 years, providing strategic advice and organizing and structuring financings to numerous early stage companies in the junior resource sector. She brings knowledge of finance, accounting and public markets to NexgenRx. She has served in the capacity of corporate secretary for several TSX-V listed companies. Ms. Brennan holds Business Administration and Bachelor of Commerce degrees from the University of Victoria and Royal Roads University, respectively.
공시 • Jun 15NexgenRx Inc. Declares Dividend in Respect of All of Its Outstanding Common Shares, Payable on or Before June 30, 2024NEXGENRX INC. announced that a dividend in the amount of $0.005 has been declared in respect of all of its outstanding common shares. This dividend will be payable on or before June 30, 2024 to all shareholders of record as at the close of business on June 24, 2024.
공시 • May 18Charles Burns Tenders Resignation as Director of NexgenRx IncNexgenRx Inc. announced that at the annual and special meeting of shareholders held on May 16, 2024, one of the Directors, Charles Burns was duly elected although the number of votes 'Withheld' exceeded the number of votes cast 'For' his election and based on the Company's Majority Voting Policy, Mr. Burns has tendered his resignation as a director of the Company. The Board has determined to delay acceptance of Mr. Burns' resignation until such time as a qualified candidate can be appointed to fill the vacancy created by this resignation, which is expected to occur on or before September 30, 2024.
공시 • Apr 03NexgenRx Inc., Annual General Meeting, May 16, 2024NexgenRx Inc., Annual General Meeting, May 16, 2024.
공시 • Dec 30NEXGENRX INC. Announces the Retirement of Dave Bennett from its Board of DirectorsNEXGENRX INC. announced the retirement of Dave Bennett from its Board of Directors as he has accepted a senior executive role in the industry and as such will be devoting 100% of his time to this new endeavour.
공시 • Dec 21NEXGENRX Inc Announces Declaration of Dividend, Payable on or Before January 4, 2024NEXGENRX INC announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before January 4, 2024 to all shareholders of record as at the close of business on December 29, 2023.
공시 • Jun 16NexgenRx Inc. Announces Declaration of Dividend in Respect of All of Its Outstanding Common Shares , Payable on or Before June 30, 2023NEXGENRX INC. announced that a dividend in the amount of one-half of one cent per share ($0.005) has been declared in respect of all of its outstanding common shares and series 1 preferred shares. This dividend will be payable on or before June 30, 2023 to all shareholders of record as at the close of business on June 23, 2023. As of the date of this press release, there are a total of 70,335,883 common shares and 6,600,000 series 1 preferred shares issued and outstanding.
공시 • May 19NexgenRx Inc. Appoints Dave Bennett as New DirectorNexgenRx Inc. at its AGM held on May 19, 2023, approved the election of Mr. Dave Bennett as new director. Mr. Bennett is a seasoned senior executive and actuary with more than 30 years' experience working in the life insurance and wealth management industries. Most recently, he was at The Equitable Life of Canada, where he led the Group Benefits business for six years. Prior to that, he was the Chief Financial Officer of the company, responsible for all financial oversight, strategic planning and corporate business development. He also has extensive experience in strategy, with time spent at McKinsey & Co, and led the Mergers and Acquisitions function at Manulife. Mr. Bennett attained his ICD.D in 2022 and has served on a number of not-for-profit boards such as Grand River Hospital, the Waterloo District School Board, and as the Chair of an independent school. He also has considerable experience working with boards as management, having been accountable to the Audit and Pension committees of Equitable Life's Board of Directors for 7 years, and leading strategic reviews.